Stockholm, Sweden-based Affibody is highlighting progress across its radiopharmaceutical pipeline at EANM, leading with phase I data on its radioligand therapy candidate ABY-271 in HER2-positive metastatic breast cancer.
Among the company’s 10 presentations are the following:
Safety and biodistribution data from the first-in-human phase I trial of lutetium-177 (Lu-177)-labelled ABY-271 in patients with HER2-positive metastatic breast cancer (EP-0981).
Whole-body PET/CT with the gallium-68-labelled HER2 imaging agent tezatabep matraxetan (ABY-025), showing variation in HER2 expression across lesions in advanced gastroesophageal adenocarcinoma.
The design of HER2-Ex PET, a prospective, open-label study testing whether tezatabep matraxetan PET can predict response to HER2 antibody-drug conjugates in metastatic breast cancer.
A preclinical comparison of terbium-161 and Lu-177 in affibody-mediated pretargeting of HER2.
Preclinical work on affibody molecules targeting B7-H3 for radionuclide therapy, including in neuroblastoma.
Other abstracts cover pretargeted delivery of actinium-225, harmonization of image quality and activity quantification in a multicentre PET study, and dosimetry for a F-18 HER2 PET tracer.
